Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL (1997) Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor, J Clin Invest, 100(6): 1557-1565.
Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y (2009) Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Bioch Biophy Res Commun 390:809–814.
Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H (2010) Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59(4):1030-7.
Arita K, Hotokezaka H, Hashimoto M, Nakano-Tajima T, Kurohama T, Kondo T, Darendeliler MA, Yoshida N (2016) Effects of diabetes on tooth movement and root resorption after orthodontic force application in rats. Orthod Craniofac. Res19:83–92.
Aronoff DM, Canetti C, Serezani CH, Luo M, Peters-Golden M (2005) Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J Immunol 174: 595–599.
Aubert RE, Herrera V, Chen W, Haffner SM, Pendergrass M (2010) Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes, Diabetes Obes Metab, 12(8): 716-721.
Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A (2000) Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts, J Biol Chem 275(7): 4858-4864.
Bazelier MT, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, Vestergaard P, de Vries F (2012) Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?, Pharmacoepidemiol Drug Saf, 21(5): 507-514.
Bazelier MT, Vestergaard P, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, de Vries F (2012) Risk of fracture with thiazolidinediones: disease or drugs?, Calcif Tissue Int 90(6): 450-457.
Betteridge DJ (2011) Thiazolidinediones and fracture risk in patients with Type 2 diabetes, Diabet Med 28(7): 759-771.
Bilezikian JP, Josse RG, Eastell R, Lewiecki EM, Miller CG, Wooddell M, Northcutt AR, Kravitz BG, Paul G, Cobitz AR, Nino AJ, Fitzpatrick LA (2013) Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus, J Clin Endocrinol Metab, 98(4): 1519-1528.
Bostanci N, Allaker RP, Belibasakis GN, Rangarajan M, Curtis MA, Hughes FJ, McKay IJ (2007) Porphyromonas gingivalis antagonises Campylobacter rectus induced cytokine production by human monocytes, Cytokine, 39(2): 147-156.
Braga SMG., Taddei SRA, Andrade I., Queiroz-Junior CM, Garlet GP, Repeke CE, Teixeira MM, da Silva TA (2011) Effect of diabetes on orthodontic tooth movement in a mouse model. Eur. J. Oral Sci 119:7–14.
Brubaker PL(2007), Incretin-based therapies: mimetics versus protease inhibitors, Trends Endocrinol Metab, 18(6): 240-245.
Cao YY, Chen ZW, Gao YH (2015) Exenatide reduces tumor necrosis factor-α-induced apoptosis in cardiomyocytes by alleviating mitochondrial dysfunction. Chin Med J (Engl) 128(23):3211–3218.
Chiang CY, Kyritsis G, Graves DT, Amar S (1999) Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide, Infect Immun, 67(8), 4231-4236.
Chung YH, Chang EJ, Kim SJ, Kim HH, Kim HM, Lee SB, Ko JS (2006) Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts, J Periodontal Res, 41(4): 288-296.
Dorecka M, Siemianowicz K, Francuz T (2013). Exendin-4 and GLP-1 decreases induced expression of ICAM-1, VCAM-1 and RAGE in human retinal pigment epithelial cells. Pharmacol Rep 65(4):884–890.
Drucker DJ (2003) Glucagon-like peptide-1 and the islet beta-cell: Augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144:5145–5148.
Dumitrescu AL, Abd-El-Aleem S, Morales-Aza B, Donaldson LF (2004) A model of periodontitis in the rat: effect of lipopolysaccharide on bone resorption, osteoclast activity, and local peptidergic innervation, J Clin Periodontol, 31(8): 596-603.
Fan R, Kang Z, He L, Chan J, Xu G (2011) Exendin-4 Improves Blood Glucose Control in Both Young and Aging Normal Non-Diabetic Mice, Possible Contribution of Beta Cell Independent Effects. PLoS One 6(5):e20443.
Fujimura Y, Kitaura H, Yoshimatsu M, Eguchi T, Kohara H, Morita Y (2009) Influence of bisphosphonates on orthodontic tooth movement in mice. Eur J Orthod31(6):572–577.
Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ (2002), TNFalpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL, Endocrinology 143(3):1108-1118.
Garber AJ (2011) Long-acting glucagon-like peptide 1 receptor agonists. A review of their efficacy and tolerability. Diabetes Care 34(suppl 2):S279– 84.
Garczorz W, Gallego-Colon E, Kosowska A (2018) Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation. Cardiovasc Ther 36:1755-5922
Garlet GP, Cardoso CR, Silva TA, B. R. Ferreira, M. J. Avila-Campos, F. Q. Cunha and J. S. Silva (2006), Cytokine pattern determines the progression of experimental periodontal disease induced by Actinobacillus actinomycetemcomitans through the modulation of MMPs, RANKL, and their physiological inhibitors, Oral Microbiol Immunol, 21(1), 12-20.
Hakami Z, Kitaura H, Kimura K, Ishida M, Sugisawa H, Ida H (2015) Effect of interleukin-4 on orthodontic tooth movement and associated root resorption. Eur J Orthod 37(1):87–94.
Holst JJ (2007) The physiology of glucagon-like peptide 1, Physiol Rev, 87(4): 1409-1439.
Kanzaki H., Chiba M., Takahashi I., Haruyama N., Nishimura M., Mitani H. Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement. J. Dent. Res. 2004;83:920–925.
Kikuchi T, Matsuguchi T, Tsuboi N, Mitani A, Tanaka S, Matsuoka M, Yamamoto G, Hishikawa T, Noguchi T, Yoshikai Y (2001) Gene expression of osteoclast differentiation factor is induced by lipopolysaccharide in mouse osteoblasts via Toll-like receptors, J Immunol, 166(5): 3574-3579.
Kimura K, Kitaura H, Fujii T, Hakami ZW, Takano-Yamamoto T (2012) Anti-c-Fms antibody inhibits lipopolysaccharide-induced osteoclastogenesis in vivo, FEMS Immunol Med Microbiol, vol. 64(2): 219-227.
Kitaura H, Kimura K, Ishida M, Kohara H, Yoshimatsu M, Takano-Yamamoto T (2013) Immunological reaction in TNF-alpha-mediated osteoclast formation and bone resorption in vitro and in vivo, Clin Dev Immunol, 2013: 181849.
Kitaura H, Sands MS, Aya K, Zhou P, Hirayama T, Uthgenannt B, Wei S, Takeshita S, Novack DV, Silva MJ, Abu-Amer Y, Ross FP, Teitelbaum SL (2004) Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo, J Immunol, 173(8)4838-4846.
Kitaura H, Yoshimatsu M, Fujimura Y, Eguchi T, Kohara H, Yamaguchi A (2008) An anti-c-Fms antibody inhibits orthodontic tooth movement. J Dent Res 87(4):396–400.
Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL (2005) M-CSF mediates TNF-induced inflammatory osteolysis, J Clin Invest, 115(12): 3418-3427.
Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction, J Exp Med 191(2): 275-286.
Korner M, Stockli M, Waser B, Reubi JC (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. Journal of Nuclear Medicine 48:736–743.
Lee YS, Jun HS (2016) Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Mediat Inflamm 2016:3094642.
Liu H, Zheng J, Zheng T, Wang P (2019) Exendin-4 regulates Wnt and NF-κB signaling in lipopolysaccharide-induced human periodontal ligament stem cells to promote osteogenic differentiation. Int Immunopharmacol 75:105801.
Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis, CMAJ, 180(1): 32-39.
Lopatiene K, Dumbravaite A (2008) Risk factors of root resorption after orthodontic treatment. Stomatologija 10(3):89–95.
Ma X, Hui H, Liu Z, He G, Hu J, Meng J, Guan L, Luo X (2009) Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation, Diabetes Obes Metab, 11(10): 953-965.
Ma X, Meng J, Jia M, Bi L, Zhou Y, Wang Y, Hu J, He G, Luo X (2013) Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats, J Bone Miner Res, 28(7):1641-1652.
Mabilleau G, Mieczkowska A, Chappard D (2014) Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials, J Diabetes, 6(3): 260-266.
Mansur SA, Mieczkowska A, Flatt PR, Chappard D, Irwin N, Mabilleau G (2019) The GLP-1 receptor agonist exenatide ameliorates bone composition and tissue material properties in high fat fed diabetic mice. Front Endocrinol 10:51.
Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects, Diabetes, vol. 53(3): 654-662.
Meng J, Ma X, Wang N, Jia M, Bi L, Wang Y (2016) Activation of GLP-1 Receptor Promotes Bone Marrow Stromal Cell Osteogenic Differentiation through beta-Catenin. Stem Cell Reports 6:633.
Mieczkowska A, Irwin N, Flatt PR, Chappard D, Mabilleau G (2013) Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality. Bone 56:337–342.
Moayer A, Mohamadpour M, Mousavi SF, Shirzadpour E, Mohamadpour S, Amraei M (2017) Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis, Ther Clin Risk Manag 13:455-468.
Montagnani A, Gonnelli S (2013) Antidiabetic therapy effects on bone metabolism and fracture risk, Diabetes Obes Metab, 15 (9):784-791, 2013.
Mormann M, Thederan M, Nackchbandi I, Giese T, Wagner C, Hansch GM (2008) Lipopolysaccharides (LPS) induce the differentiation of human monocytes to osteoclasts in a tumour necrosis factor (TNF) alpha-dependent manner: a link between infection and pathological bone resorption, Mol Immunol, 45(12), 3330-3337.
Nielsen LL, Baron AD (2003) Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes, Curr Opin Investig Drugs, 4(4): 401-405.
Nuche-Berenguer B, Lozano D, Gutierrez-Rojas I, Moreno P, Mariñoso ML, Esbrit P, Villanueva-Peñacarrillo ML (2011) GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol 209:203–210.
Nuche-Berenguer B, Moreno P, Esbrit P, Dapia S, Caeiro JR, Cancelas J, Haro-Mora JJ, Villanueva-Penacarrillo ML (2009) Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states, Calcif Tissue Int, 84(6): 453-461.
Nuche-Berenguer B, Moreno P, Portal-Nunez S, Dapia S, Esbrit P, Villanueva-Penacarrillo ML (2010) Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states, Regul Pept, 159(1-3): 61-66.
Ogawa S Kitaura H, Kishikawa A, Qi J, Shen WR, Ohori F, Noguchi T, Marahleh A, Nara Y, Ochi Y, Mizoguchi I. (2019). TNF-α is responsible for the contribution of stromal cells to osteoclast and odontoclast formation during orthodontic tooth movement. PLoS One 14(10): e0223989.
Orcel P, Feuga M, Bielakoff J, De Vernejoul MC (1993) Local bone injections of LPS and M-CSF increase bone resorption by different pathways in vivo in rats, Am J Physiol, 264(3): 391-397.
Pereira M, Gohin S, Roux JP, Fisher A, Cleasby ME, Mabilleau G (2017) Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus. Front Endocrinol 8:327.
Pereira M, Jeyabalan J, Jørgensen CS (2015) Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone 81:459-67.
Pereira M, Jeyabalan J, Jorgensen CS, Hopkinson M, Al-Jazzar A, Roux JP, Chavassieux P, Orriss IR, Cleasby ME, Chenu C (2015) Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice, Bone, 81: 459-467.
Plut A, Sprogar Š, Drevenšek G (2015). Bone remodeling during orthodontic tooth movement in rats with type 2 diabetes. Am J Orthod Dentofacial Orthop148:1017‐1025.
Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction, J Clin Invest 110(10): 1419-1427.
Saeed J, Kitaura H, Kimura K, Ishida M, Sugisawa H, Ochi Y, Kishikawa A, Takano-Yamamoto T (2016) IL-37 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption in vivo, Immunol Lett, 175: 8-15.
Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, Ushikubi F, Narumiya S, Segi E, Sugimoto Y, Ichikawa A, Nakao K (2000) Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide, J Bone Miner Res, 15(2): 218-227.
Schwartz AV, Vittinghoff E, Bauer DC, Hillier TC, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM (2011) Study of Osteoporotic Fractures Research, G. Osteoporotic Fractures in Men Research, A. Health and G. Body Composition Research, Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes, JAMA 305(21): 2184-2192.
Shen WR, Kimura K, Ishida M, Sugisawa H, Kishikawa A, Shima K, Ogawa S, Qi J, Kitaura H (2018) The glucagon-like Peptide-1 receptor agonist Exendin-4 inhibits lipopolysaccharide-induced osteoclast formation and bone resorption via inhibition of TNF-α expression in macrophages. J Immunol Res 2018:5783639.
Teitelbaum SL (2000) Bone resorption by osteoclasts, Science 289(5484):1504-1508.
Teitelbaum SL (2007) Osteoclasts: what do they do and how do they do it? Am J Pathol170(2): 427-435.
Tyrovola JB, Spyropoulos MN, Makou M, Perrea D (2008) Root resorption and the OPG/RANKL/RANK system: A mini review. J Oral Sci 50:367– 76.
Verna C, Dalstra M, Melsen B (2000) The rate and the type of orthodontic tooth movement is influenced by bone turnover in a rat model. Eur J Orthod 22:343–52.
Verhaeghe J, Van Herck E, Visser WJ, Suiker AM, Thomasset M, Einhorn TA, Faierman E, Bouillon R (1990) Bone and mineral metabolism in BB rats with long-term diabetes: decreased bone turnover and osteoporosis. Diabetes 39:477–482.
Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk, Diabetologia 48(7): 1292-1299.
Wada N, Maeda H, Yoshimine Y, Akamine A (2004) Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha, Bone, vol. 35(3), 3: 629-635.
Walsh JS, Vilaca T (2017) Obesity, Type 2 Diabetes and Bone in Adults, Calcif Tissue Int 100(5): 528-535.
Wang N, Gao J, Jia M, Ma X, Lei Z, Da F, Yan F, Zhang H, Zhou Y, Li M (2017) Exendin-4 induces bone marrow stromal cells migration through bone marrow-derived macrophages polarization via PKA-STAT3 signaling pathway. Cell Physiol Biochem 44(5):1696-1714.
Wei Q, Sun YQ, Zhang J (2012) Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line. Peptides 37(1):18–24.
World Health Organization (2016) Global Report on Diabetes 2016: 20-33.
Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N (2008) The murine glucagon-like peptide-1 receptor is essential for control of bone resorption, Endocrinology, 149(2): 574-579.
Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N (2008) The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinol149:574–579.
Yang CY, Jeon HH, Alshabab A (2018) RANKL deletion in periodontal ligament and bone lining cells blocks orthodontic tooth movement. Intl J Oral Sci 10(1):31–39.
Yoshimatsu M, Kitaura H, Fujimura Y, Kohara H, Morita Y, Eguchi T (2012). Inhibitory effects of IL-12 on experimental tooth movement and root resorption in mice. Arch. Oral Biol 57: 36–43.
Zhang YS, Weng WY, Xie BC, Meng Y, Hao YH, Liang YM, Zhou ZK (2018) Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials. Osteoporos. Int 29:2639–2644.
Zou W, Bar-Shavit Z (2002) Dual modulation of osteoclast differentiation by lipopolysaccharide, J Bone Miner Res, 17(7): 1211-1218
論文の公開元へ
